New Anti Radiation Drug Tests
Scientific achievement
The United States Military gives authorisation for the development of new Anti-Tad Drugs, current medication at the time is capable of forcing the digestive system to eject radiation or give people a small boost in resistance.
This was seen as inadequate to the possibility of Nuclear War, The CDC suggested a series of Hyper-fringe theoretical compounds that could neutralise radiation once it dissolves and spreads through the system.
The Project would be conducted in Japan and America for those exposed to radiation. Volunteers in service also agreed to mild radiation sickness and treatment with the new Experimental drugs. Many precautions were taken and while deaths were avoided, many early patients had medical issues that had to be tended to.
By 2023, 7th of June, Doctor Emberton discovered Compound U88 could be used as a Tablet and was observed to cause breakdown of Radioactive material in systems however is noted to stress orgrans and can damage stomachs.
By 2023, 10th of December, U88 was rejected and I5 was adopted instead with less of an effect but a quarter of the potential problems. I5-1 was made months after and the FDA began experimenting with the drug in collaboration with the CDC and Military researchers.
15-2 was then made in 2024 March 20th and finished all initial tests. I5-2 was identified as the prime 2nd Generation Anti-Rad pill with effects of Radiation resistance and acceptable breakdown of radioactive materials.
The Drug is named "Anti-Rad" and begins its next stage of tests and reviews in congress and a large list of organisations.
